iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Graham Corp

HCI Group

Limbach Holdings

Manitex

We have narrowed our search to five small-cap (market capital < $1 billion) stocks. These are: HCI, LMB, IRMD, GHM, MNTX.

5 Small Hidden Gems for the Rest of 2023

IRadimed Corporation (IRMD) Q3 2023 Earnings Call Transcript

WINTER SPRINGS, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results

Axcelis Technologies

NVIDIA

Perdoceo Education

NVIDIA (NVDA), iRadimed (IRMD), Perdoceo Education (PRDO) and Axcelis Technologies (ACLS) have been selected as the top picks with a high net income ratio.

4 Top Profitable Stocks to Invest in Using Net Income Ratio

PulteGroup

iRadimed (IRMD), PulteGroup (PHM) and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.

Top 3 Profitable Stocks to Buy Now Using Net Income Ratio

WINTER SPRINGS, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that the Company will be participating in two upcoming investor conferences.

IRADIMED CORPORATION to Participate at Upcoming Investor Conferences

iRadimed (IRMD) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why

IRadimed Corporation is unlocking value for shareholders and has a favorable long-term position in the MRI-compatible devices and monitors industry. Q2 earnings showed strong growth in sales revenue, with a shift towards international sales and significant growth in device revenues and disposables. IRMD has attractive economic characteristics, including high returns on capital and increasing post-tax margins, supporting a buy rating.

IRadimed Continues Ploughing Along With Superb Economic Characteristics

Boot Barn Hlds

Perdoceo Education (PRDO), Boot Barn (BOOT) and iRadimed (IRMD) have been selected as the top picks with a high net income ratio.

3 Top Profitable Stocks to Invest in Using Net Income Ratio

Enerplus

Helix Energy Solutions Group

Johnson & Johnson

Lam Research

Uber

Energy Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

Want to start the week ahead of the pack? Check out ‘Momentum Mondays,' where I cover the leading breakout stocks in the market, summarize the major events of the week ahead, and prepare investors for profitable trading.

Momentum Mondays: Stocks Setting up for an Epic Dip Buying Opportunity?

Alcon Inc. - Registered Shares

Artivion

Cardinal Health

Penumbra

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

Time to Buy These Medical Stocks as Earnings Approach

iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why

IRadimed (IRMD) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.27 per share a year ago.

IRadimed (IRMD) Q2 Earnings and Revenues Beat Estimates

WINTER SPRINGS, Fla., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three and six months ended June 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces Second Quarter 2023 Financial Results

WINTER SPRINGS, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 second quarter financial results before the market opens on Thursday, August 3rd. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2023 Second Quarter Financial Results Conference Call on August 3rd

HealthEquity

With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.

2 Medical Stocks to Consider Buying in June

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable

IRadimed Corporation's Q1 FY'23 results show a 26% YoY growth in revenues, driven by strong domestic and international sales. The company's economic earnings and incremental returns on capital indicate a strong growth strategy and potential for scalability. A buy rating is reiterated with a revised price target of $95 per share, representing a ~100% upside potential.

IRadimed: Incremental Profit Gains, Reiterate Buy

WINTER SPRINGS, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), was recently named on Forbes' latest list of America's Best Small Companies for 2023. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Named a 2023 Best Small Company in America by Forbes

IRadimed Corporation (NASDAQ:IRMD ) Q1 2023 Earnings Conference Call May 4, 2023 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Scott Henry - ROTH Capital Operator Welcome to IRadimed Corporation First Quarter of the 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

IRadimed Corporation (IRMD) Q1 2023 Earnings Call Transcript

IRadimed (IRMD) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.22 per share a year ago.

IRadimed (IRMD) Surpasses Q1 Earnings and Revenue Estimates

WINTER SPRINGS, Fla., May 04, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three months ended March 31, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces First Quarter 2023 Financial Results

WINTER SPRINGS, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 first quarter financial results before the market opens on Thursday, May 4th. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2023 First Quarter Financial Results Conference Call on May 4th

AAON

MercadoLibre

Northeast Community Bancorp

MercadoLibre (MELI), iRadimed (IRMD), Northeast Community Bancorp (NECB) and AAON (AAON) have been selected as the top picks with a high net income ratio.

4 Best Profitable Stocks to Buy Banking on Net Income Ratio

WINTER SPRINGS, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, President and Chief Executive Officer of the Company, will be presenting at the 35th Annual Roth Conference in Laguna Niguel, CA. Mr. Susi is scheduled for a live fireside chat on Monday, March 13, at 11:30 am PT.

News for iRadimed Stock (IRMD)